CN102058871B - 一种具有抗肿瘤作用的中药有效部位组合物及其制备方法 - Google Patents
一种具有抗肿瘤作用的中药有效部位组合物及其制备方法 Download PDFInfo
- Publication number
- CN102058871B CN102058871B CN 201010558679 CN201010558679A CN102058871B CN 102058871 B CN102058871 B CN 102058871B CN 201010558679 CN201010558679 CN 201010558679 CN 201010558679 A CN201010558679 A CN 201010558679A CN 102058871 B CN102058871 B CN 102058871B
- Authority
- CN
- China
- Prior art keywords
- add
- amount
- radix astragali
- hedyotidis diffusae
- herba hedyotidis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 239000008187 granular material Substances 0.000 claims abstract description 15
- 238000002347 injection Methods 0.000 claims abstract description 13
- 239000007924 injection Substances 0.000 claims abstract description 13
- 239000006187 pill Substances 0.000 claims abstract description 12
- 230000036039 immunity Effects 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract description 8
- 239000006196 drop Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 147
- 239000009636 Huang Qi Substances 0.000 claims description 100
- 229930003944 flavone Natural products 0.000 claims description 55
- 235000011949 flavones Nutrition 0.000 claims description 55
- 150000004676 glycans Chemical class 0.000 claims description 55
- 229920001282 polysaccharide Polymers 0.000 claims description 55
- 239000005017 polysaccharide Substances 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 53
- 241001312741 Gekko swinhonis Species 0.000 claims description 52
- 150000002213 flavones Chemical class 0.000 claims description 51
- 239000000706 filtrate Substances 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 35
- 230000006837 decompression Effects 0.000 claims description 33
- 229940079593 drug Drugs 0.000 claims description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 22
- 239000011347 resin Substances 0.000 claims description 20
- 229920005989 resin Polymers 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 239000012188 paraffin wax Substances 0.000 claims description 18
- 239000000758 substrate Substances 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 17
- 239000012567 medical material Substances 0.000 claims description 17
- 238000004321 preservation Methods 0.000 claims description 16
- 238000004064 recycling Methods 0.000 claims description 16
- 238000001556 precipitation Methods 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 238000002844 melting Methods 0.000 claims description 11
- 230000008018 melting Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 102000057297 Pepsin A Human genes 0.000 claims description 9
- 108090000284 Pepsin A Proteins 0.000 claims description 9
- 102000004142 Trypsin Human genes 0.000 claims description 9
- 108090000631 Trypsin Proteins 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000009413 insulation Methods 0.000 claims description 9
- 229940111202 pepsin Drugs 0.000 claims description 9
- 230000000630 rising effect Effects 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 9
- 239000012588 trypsin Substances 0.000 claims description 9
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 239000001263 FEMA 3042 Substances 0.000 claims description 8
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 229920002258 tannic acid Polymers 0.000 claims description 8
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 8
- 229940033123 tannic acid Drugs 0.000 claims description 8
- 235000015523 tannic acid Nutrition 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 150000002212 flavone derivatives Chemical class 0.000 claims description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 229940107666 astragalus root Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 230000001172 regenerating effect Effects 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 6
- 239000007938 effervescent tablet Substances 0.000 abstract description 5
- 239000007901 soft capsule Substances 0.000 abstract description 5
- 239000007902 hard capsule Substances 0.000 abstract description 4
- 230000036737 immune function Effects 0.000 abstract description 4
- 238000001959 radiotherapy Methods 0.000 abstract description 4
- 240000001659 Oldenlandia diffusa Species 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 206010047700 Vomiting Diseases 0.000 abstract description 2
- 230000036528 appetite Effects 0.000 abstract description 2
- 235000019789 appetite Nutrition 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 208000002173 dizziness Diseases 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 201000002364 leukopenia Diseases 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract 2
- 241000258920 Chilopoda Species 0.000 abstract 2
- 235000006533 astragalus Nutrition 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 201000011510 cancer Diseases 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 239000012467 final product Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000000242 pagocytic effect Effects 0.000 description 14
- 241000287828 Gallus gallus Species 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 231100000614 poison Toxicity 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
- 206010061598 Immunodeficiency Diseases 0.000 description 9
- 238000012449 Kunming mouse Methods 0.000 description 9
- 241000131808 Scolopendra Species 0.000 description 9
- 241000522620 Scorpio Species 0.000 description 9
- 239000009490 scorpio Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003540 anti-differentiation Effects 0.000 description 2
- 229950005162 benexate Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 235000019636 bitter flavor Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- -1 fatty acid ester Chemical class 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Chemical class 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241001312740 Gekko japonicus Species 0.000 description 1
- 241000270291 Gekkonidae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000607292 Maguireothamnus speciosus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000270708 Testudinidae Species 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010558679 CN102058871B (zh) | 2010-11-25 | 2010-11-25 | 一种具有抗肿瘤作用的中药有效部位组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010558679 CN102058871B (zh) | 2010-11-25 | 2010-11-25 | 一种具有抗肿瘤作用的中药有效部位组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102058871A CN102058871A (zh) | 2011-05-18 |
CN102058871B true CN102058871B (zh) | 2013-04-17 |
Family
ID=43994496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010558679 Expired - Fee Related CN102058871B (zh) | 2010-11-25 | 2010-11-25 | 一种具有抗肿瘤作用的中药有效部位组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102058871B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105250987A (zh) * | 2015-11-05 | 2016-01-20 | 安徽生物肽产业研究院有限公司 | 一种用于增强免疫力的蚕蛹生物活性小肽组合物 |
CN105250989A (zh) * | 2015-11-06 | 2016-01-20 | 安徽生物肽产业研究院有限公司 | 一种用于抗疲劳的阿胶小肽组合物 |
CN112755053A (zh) * | 2019-11-05 | 2021-05-07 | 湖南许丰现代农业股份有限公司 | 一种中药天龙的加工工艺 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1954849A (zh) * | 2005-10-26 | 2007-05-02 | 黄振华 | 一种白花蛇舌草、人参和黄芪配伍的抗肿瘤的药物组合物 |
-
2010
- 2010-11-25 CN CN 201010558679 patent/CN102058871B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1954849A (zh) * | 2005-10-26 | 2007-05-02 | 黄振华 | 一种白花蛇舌草、人参和黄芪配伍的抗肿瘤的药物组合物 |
Non-Patent Citations (3)
Title |
---|
代龙.《全蝎不同工艺提取物抗凝血及溶栓作用的比较研究》.《西北药学杂志》.2009,第24卷(第2期),第114-116页. * |
代龙等.《蜈蚣不同工艺提取物抗凝血及溶栓作用的比较研究》.《中华中医药学刊》.2009,第27卷(第8期),第1777-1779页. * |
李钦青等.《壁虎不同提取工艺成分抗肿瘤作用的研究》.《时珍国医国药》.2010,第21卷(第7期),第1629-1630页. * |
Also Published As
Publication number | Publication date |
---|---|
CN102058871A (zh) | 2011-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102058744B (zh) | 一种治疗恶性肿瘤的中药组合物及其制备方法 | |
CN101596230B (zh) | 一种治疗肝病的药物组合物 | |
CN104740541A (zh) | 一种保肝解毒恢复肝功能的保健中药粉 | |
CN103599215A (zh) | 一种降糖药物 | |
CN102058871B (zh) | 一种具有抗肿瘤作用的中药有效部位组合物及其制备方法 | |
CN102526345B (zh) | 一种治疗高血压的中药组合物 | |
CN102145120B (zh) | 一种适于制备治疗ii型糖尿病的中药组合物 | |
CN1558768A (zh) | 一种中药组合物及其制备方法 | |
CN103520318B (zh) | 一种增强免疫功能的中药组合物及其制备方法 | |
CN103705578B (zh) | 具有降血脂与抑制血糖升高作用的中药制剂及其制备方法 | |
CN101757408A (zh) | 一种治疗红斑狼疮的药物及其制备方法 | |
CN104491242B (zh) | 一种治疗认知功能障碍的药物组合物及其制备方法和用途 | |
CN103599343A (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
CN100506260C (zh) | 治疗粘膜性溃疡的复方制剂 | |
CN103223149A (zh) | 一种治疗肺癌的中草药组合物 | |
CN101822793B (zh) | 一种治疗糖尿病的保健茶及其制备方法 | |
CN105250987A (zh) | 一种用于增强免疫力的蚕蛹生物活性小肽组合物 | |
CN101204520B (zh) | 一种防治亚健康疲劳的药物组合物及其制备方法 | |
CN102366480A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN103860942A (zh) | 用于治疗痰浊结聚型鼻咽癌的药物及其制备方法 | |
CN106376928A (zh) | 一种辅助降血糖的复方铁皮石斛保健品制备方法 | |
CN102366481B (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN102406913A (zh) | 一种治疗郁证的中药组合物 | |
CN106344808A (zh) | 一种辅助降血糖的复方铁皮石斛保健品 | |
CN102366596B (zh) | 一种治疗糖尿病的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANJING TIANYUAN PEPTIDE SCIENCE AND TECHNOLOGY CO Free format text: FORMER OWNER: DAI LONG Effective date: 20150618 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150618 Address after: 210033, room 402, building F7, Jiangsu life science and Technology Innovation Park, No. 9 weft Lu, Qixia District, Jiangsu, Nanjing Patentee after: NANJING TIANYUAN PEPTIDE PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: 250355 College of science and technology, Changqing District, Shandong City, Ji'nan Province, Shandong University of Traditional Chinese Medicine Patentee before: Dai Long |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130417 Termination date: 20161125 |